Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.

Trial Details

NCT ID

NCT07126236

Phase

PHASE2

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Epcoritamab
Epcoritamab, tafasitamab and lenalidomide

Locations (sample)

Zaragoza, Aragon, Spain|41.65606,-0.87734
Burgos, Castille and León, Spain|42.34106,-3.70184
Badalona, Catalonia, Spain|41.45004,2.24741
Barcelona, Catalonia, Spain|41.38879,2.15899
Cáceres, Extremadura, Spain|39.47649,-6.37224

Key Eligibility Criteria

Written informed consent must be obtained before any study-specific assessment is performed.
Age \>18 years
Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell …
Relapsed disease is defined as complete remission to first line therapy followed by a recurrence of the disease after a minimum of 6 months of comp…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →